Suven Life Sciences balance sheet

As of Mar 2026

Total assets: ₹624cr+361.8% on Mar 2025
Shareholders' equity: ₹591cr+437.7% on Mar 2025
Total debt: ₹0.0crNo figure a year before
Cash and investments: ₹8.3cr−77.8% on Mar 2025

₹ crore except per share

Tap a line for its trend	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

Current assets
Non-current assets					FY22 and earlierEvery year the company has filed comes with Alpha Plus.
	55.7	59.5	27.5	35.7
	3.6	0.0	0.0	0.0
	0.1	0.2	0.2	1.5
	18.0	0.0	0.0	100
	18.0	0.0	0.0	100
	0.0	—	0.5	0.1
	77.5	59.7	28.2	137
	0.1	0.2	0.7	0.0
	0.0	22.3	75.9	46.3
	1.5	1.3	1.3	0.8
	8.3	15.0	14.9	37.0
	329	22.7	149	147
	184	0.1	2.2	4.8
	523	61.4	243	236
	21.3	12.6	10.8	8.4
	547	75.5	257	252
	624	135	285	389
Equity
	26.4	21.8	21.8	21.8
	565	88.2	248	354
	591	110	270	375
	591	110	270	375
Liabilities
	—	—	0.0	0.6
	0.0	0.0	0.0	0.6
	1.9	1.7	1.3	1.9
	1.9	1.7	1.3	2.5
	4.8	5.2	2.1	1.7
	22.3	0.6	9.8	7.9
	27.1	5.8	11.9	9.6
	1.5	1.6	1.1	1.0
	2.2	16.0	0.5	0.5
	30.9	23.5	13.5	11.1
	32.8	25.2	14.9	13.6
	624	135	285	389
Assets — additional as-filed lines
	1.9	1.2	1.8	7.0
Trade payables — MSME split
	0.4	0.4	—	—
	4.4	4.8	—	—

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

SUVEN₹264.20

Suven Life Sciences Limited

· Pharma & Health

₹ CrorePeersVIMTALABS TAKEMcap ₹6,967 Cr

View

In ₹ Crore except Per Share As of	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/06/2026
Non-current Assets
+ Property, Plant & Equipment	35.7	27.5	59.5	55.7	55.7
+ Capital Work-in-Progress	0.0	0.0	0.0	3.6	3.6
+ Other Intangibles	1.5	0.2	0.2	0.1	0.1
+ Other Non-current Financial Assets	100.0	0.0	0.0	18.0	18.0
Non-current Financial Assets	100.0	0.0	0.0	18.0	18.0
+ Other Non-current Assets	0.1	0.5	—	0.0	0.0
Total Non-current Assets	137.3	28.2	59.7	77.5	77.5
Current Assets
+ Inventories	0.0	0.7	0.2	0.1	0.1
+ Current Investments	46.3	75.9	22.3	0.0	0.0
+ Trade Receivables	0.8	1.3	1.3	1.5	1.5
+ Cash & Cash Equivalents	37.0	14.9	15.0	8.3	8.3
+ Other Bank Balances	147.3	149.0	22.7	329.2	329.2
+ Other Current Financial Assets	4.8	2.2	0.1	184.4	184.4
Current Financial Assets	236.2	243.4	61.4	523.3	523.3
+ Other Current Assets	8.4	10.8	12.6	21.3	21.3
Total Current Assets	251.6	256.7	75.5	546.7	546.7
Total Assets	388.9	284.9	135.2	624.2	624.2
Equity
+ Equity Share Capital	21.8	21.8	21.8	26.4	26.4
+ Other Equity / Reserves	353.5	248.2	88.2	565.0	565.0
Equity — Owners of Parent	375.3	270.0	110.0	591.4	591.4
Total Equity	375.3	270.0	110.0	591.4	591.4
Liabilities
+ Other Non-current Financial Liab	0.6	0.0	—	—	—
Non-current Financial Liabilities	0.6	0.0	0.0	0.0	0.0
+ Provisions — Non-current	1.9	1.3	1.7	1.9	1.9
Non-current Liabilities	2.5	1.3	1.7	1.9	1.9
+ Trade Payables	1.7	2.1	5.2	4.8	4.8
+ Other Current Financial Liab	7.9	9.8	0.6	22.3	22.3
Current Financial Liabilities	9.6	11.9	5.8	27.1	27.1
+ Provisions — Current	1.0	1.1	1.6	1.5	1.5
+ Other Current Liabilities	0.5	0.5	16.0	2.2	2.2
Current Liabilities	11.1	13.5	23.5	30.9	30.9
Total Liabilities	13.6	14.9	25.2	32.8	32.8
Total Equity & Liabilities	388.9	284.9	135.2	624.2	624.2
Assets — additional as-filed lines
+ Current Tax Assets	7.0	1.8	1.2	1.9	1.9
Trade Payables — MSME split
+ Dues to Micro & Small — Current	—	—	0.4	0.4	0.4
+ Dues to Other Creditors — Current	—	—	4.8	4.4	4.4

As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.